Roustai Geraylow Kiarash, Hemmati Romina, Kadkhoda Sepideh, Ghafouri-Fard Soudeh
Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran.
Department of Medical Genetics, Tehran University of Medical Sciences, Tehran, Iran.
Gene Rep. 2022 Sep;28:101641. doi: 10.1016/j.genrep.2022.101641. Epub 2022 Jul 16.
Coronavirus disease 2019 (COVID-19) is regarded as a challenge in health system. Several studies have assessed the immune-related aspect of this disorder to identify the host-related factors that affect the course of COVID-19. microRNAs (miRNAs) as potent regulators of immune responses have gained much attention in this regard. Recent studies have shown aberrant expression of miRNAs in COVID-19 in association with disease course. Differentially expressed miRNAs have been enriched in pathways related with inflammation and antiviral immune response. miRNAs have also been regarded as potential therapeutic targets in COVID-19, particularly for management of pathological consequences of COVID-19. In the current review, we summarize the data about dysregulation of miRNAs in COVID-19.
2019冠状病毒病（COVID-19）被视为卫生系统面临的一项挑战。多项研究评估了这种疾病的免疫相关方面，以确定影响COVID-19病程的宿主相关因素。微小RNA（miRNA）作为免疫反应的有效调节因子，在这方面受到了广泛关注。最近的研究表明，COVID-19中miRNA的异常表达与疾病病程相关。差异表达的miRNA在与炎症和抗病毒免疫反应相关的途径中富集。miRNA也被视为COVID-19的潜在治疗靶点，特别是用于管理COVID-19的病理后果。在本综述中，我们总结了有关COVID-19中miRNA失调的数据。
